SalioGen Therapeutics
SalioGen Therapeutics is a biotechnology company developing genetic medicines for Stargardt disease and cystic fibrosis using its proprietary Gene Coding™ technology, headquartered in Lexington, Massachusetts.
Overview of SalioGen Therapeutics
SalioGen Therapeutics is a biotechnology company headquartered in Lexington, Massachusetts. They specialize in developing next-generation genetic medicines using their proprietary Gene Coding™ technology. This innovative technology allows for the precise integration of large or multiple whole genes into the genome without the need for double-strand breaks or guide RNA.
Gene Coding™ Technology
SalioGen Therapeutics leverages its unique Gene Coding™ technology to integrate genes at precise locations within the genome. This approach avoids double-strand breaks or the need for guide RNA, making it a significant advancement in genetic medicine. This technology is designed to support one-time treatments for various diseases, offering a potentially transformative impact on patient care.
One-Time Treatments for Diseases
SalioGen Therapeutics is focused on developing one-time treatments for diseases such as Stargardt disease and cystic fibrosis. Their unique approach aims to deliver long-lasting therapeutic benefits through their Gene Coding™ technology. The company has already selected a development candidate for ABCA4-mediated Stargardt Disease and plans to advance it into clinical trials in the first half of 2025.
Financial Milestones
SalioGen Therapeutics has successfully secured significant funding to advance its innovative genetic medicine platform. In March 2021, the company raised $115 million in an oversubscribed Series B financing round. Additionally, they raised $20 million in Series A financing to support the development of their novel genome engineering platform for non-viral gene therapy.
Upcoming Conferences and Presentations
SalioGen Therapeutics is set to present data at major 2024 annual meetings, including the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Gene & Cell Therapy (ASGCT). These presentations will provide insights into the ongoing research and development initiatives at the company.